Ranitidine Tab n / 150mg film about 20 pieces of ozone

Description

Composition
Active substance:
1 tablet contains ranitidine hydrochloride – 168 mg, calculated as ranitidine – 150 mg.
Product form:
Tablets, film-coated, 150 mg. 10, 20, 25, 30 tablets were placed in blisters of PVC film and aluminum foil printed patent. 10, 20, 30, 40, 50, 60 tablets were placed in plastic jars for medicaments. One jar or 1, 2, 3, 4, 5, 6 or 10, the contour of cellular packaging together with instructions for use placed in a cardboard box (pack).
Contraindications
Hypersensitivity to ranitidine or other components of the formulation. Pregnancy, lactation. Children up to age 12 years.
Precautions – kidney and / or liver failure, cirrhosis with portosystemic encephalopathy a history of acute porphyria (including history), immunosuppression.
Dosage
150 mg
Indications
Treatment and prevention of relapse of gastric ulcer and duodenal ulcer; ulcers of the stomach and duodenum 12 associated with nonsteroidal antiinflammatory drugs (NSAIDs); reflux esophagitis, erosive esophagitis; Zollinger-Ellison syndrome; treatment and prevention of post-operative, “stress” ulcers of the upper gastrointestinal tract; the prevention of recurrence of bleeding from the upper gastrointestinal tract; Prevention of aspiration of gastric juice in operations under general anesthesia (Mendelson’s syndrome).
pharmachologic effect
Pharmacological group:
Gastric glands secretion depressing agent – histamine H2 receptor blocker.
Pharmacological properties:
Ranitidine is an antagonist of the histamine H2 receptors of the parietal cells of the gastric mucosa. Reduces both basal and stimulated acid secretion induced by stimulation of baroreceptors, food loading, the action of hormones and biogenic stimulators (gastrin, histamine, pentagastrin). Ranitidine reduces the amount of gastric juice and the content of hydrochloric acid in it, increases the pH of stomach contents which leads to reduction in pepsin activity. Following oral administration at therapeutic doses, did not affect prolactin levels. Inhibits microsomal enzymes. The duration of action following a single dose up to 12 hours.
Conditions of supply of pharmacies
Without a prescription.
Dosing and Administration
Ranitidine taking of meals, without chewing, with a small amount of liquid. Adults and children over 12 years: Peptic ulcer and 12 duodenal ulcer. To treat exacerbations appoint 0.15 g of 2 times a day (morning and evening), or 0.3 g per night. If necessary – 0.3 g 2 times per day. Duration of treatment – 4 – 8 weeks. For the prevention of exacerbations appoint 0.15 g per night. Ulcers associated with NSAID. Assign to 0.15 g of 2 times a day, or 0.3 g per night for 8-12 weeks. Prevention of ulceration when taking NSAIDs – 0.15 g 2 times per day. Postoperative “stress” ulcers. Assign to 0.15 g of 2 times a day for 4-8 weeks. Reflux esophagitis, erosive esophagitis. Assign to 0.15 g of 2 times a day, or 0.3 g per night. If necessary, the dose may be increased to 0.15 g 4 times a day. The course of treatment 8-12 weeks. Zollinger-Ellison syndrome. The starting dose of 0.15 g three times a day, the dose can be increased if necessary. Prevention of recurrent bleeding. 0.15 g of 2 times a day. Prophylaxis of Mendelson’s syndrome. Administered in a dose of 0.15 g of 2 hours prior to anesthesia, as well as, preferably 0.15 g overnight. When there is an associated dysfunction of the liver may require dose reduction. Patients with renal failure when creatine clearance less than 50 mL / minute recommended dose is 0.15 g per day. Patients who are on hemodialysis, another dose administered immediately after hemodialysis.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist